Clinical Trial Update: Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics and safety study of YZJ-1139 in subjects with mild, moderate, and normal hepatic impairment, including insomnia patients, has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• YZJ-1139

Snippet

Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Conditions: Insomnia, Hepatic Impairment | Phase 1 | Status: COMPLETED